OKYO Pharma (OKYO) Net Equity Issued and Repurchased (2024 - 2026)
OKYO Pharma's (OKYO) quarterly Net Equity Issued and Repurchased came in at $23.3 million in Q1 2026, up 992.87% quarter-over-quarter from -$2.6 million in Q4 2025.
Powered by 
Analysis
OKYO Pharma (OKYO) Net Equity Issued and Repurchased (2024 - 2026) Analysis & Trends
OKYO Pharma (OKYO) has reported Net Equity Issued and Repurchased for 3 consecutive years, with $23.3 million the latest figure, recorded in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 9.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 49.20 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | OKYO Pharma | 985.60 Mn | 985.60 Mn | - | 23.32 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 23.32 Mn |
| Dec 31, 2025 | -2.61 Mn |
| Dec 31, 2024 | 6.21 Mn |